Skip to main content
. Author manuscript; available in PMC: 2017 Apr 18.
Published in final edited form as: Cell Rep. 2017 Mar 28;18(13):3167–3177. doi: 10.1016/j.celrep.2017.03.003

Figure 6. Inhibition of Olig2 phosphorylation enhances p53 function.

Figure 6

(A and B) Olig2 kinase inhibitors increase p21 level through inhibiting Olig2 phosphorylation. Olig2-null NPCs were transduced with retroviruses that express either WT-Olig2 or TPM-Olig2. p21 activation upon kinase inhibitor treatment was examined and compared between two NPC lines by western blot analysis. Cells were examined either after 24 hr treatment with 5 μM CVT313 (CDK1/2 inhibitor), or after 8 hr treatment with 10 μM CX-4945 (CK2 inhibitor) or 5 μM CHIR99021 (GSK3 inhibitor). Data were analyzed by two-way ANOVA with Sidak posttest. There is a significant difference between WT-Olig2 and TPM-Olig2 in response to Olig2 kinase inhibitors. Data are represented as mean ± SEM. **p<0.01, ***p<0.001; n=3.